ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study Comparing Liquid and Tablet Buprenorphine Formulations - 5

This study has been completed.

Sponsored by: National Institute on Drug Abuse (NIDA)
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00000302
  Purpose

The purpose of this study is to compare liquid and tablet buprenorphine formulations.


Condition Intervention Phase
Heroin Dependence
Drug: Buprenorphine
Phase III

MedlinePlus related topics:   Heroin   

Drug Information available for:   Buprenorphine    Buprenorphine hydrochloride   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Double-Blind
Official Title:   Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use
  • Retention
  • Drug craving

Estimated Enrollment:   0

Detailed Description:

Participants were inducted on either liquid or tablet buprenorphine, in a double-blind, double-dummy manner. They each reached a steady state by the second week, and were scheduled to have blood draws in weeks 3, 4, 7, 8, 11, 12, 15, and 16.

  Eligibility
Ages Eligible for Study:   21 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

M/F ages 21-50. Opiate dependence according to DSM-IV criteria. Currently enrolled in the outpatient protocol comparing liquid and tablet formulations of Buprenorphine. Agreeable to conditions of study and signed informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative-hypnotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000302

Locations
United States, California
Friends Research Institute    
      Los Angeles, California, United States, 90025

Sponsors and Collaborators

Investigators
Principal Investigator:     Walter Ling, M.D.     Friends Research Institute, Inc.    
  More Information


Study ID Numbers:   NIDA-09260-5, P50-09260-5
First Received:   September 20, 1999
Last Updated:   November 3, 2005
ClinicalTrials.gov Identifier:   NCT00000302
Health Authority:   United States: Federal Government

Study placed in the following topic categories:
Buprenorphine
Mental Disorders
Heroin Dependence
Substance-Related Disorders
Disorders of Environmental Origin
Opioid-Related Disorders

Additional relevant MeSH terms:
Sensory System Agents
Therapeutic Uses
Narcotic Antagonists
Physiological Effects of Drugs
Central Nervous System Depressants
Narcotics
Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents
Pharmacologic Actions
Analgesics, Opioid

ClinicalTrials.gov processed this record on December 03, 2008




Links to all studies - primarily for crawlers